Skip to main content
Clinical Trials/NCT03517813
NCT03517813
Completed
Not Applicable

Comparative Performance of Contrast-enhanced Spectral Mammography (CESM) and Abbreviated Breast MRI (ABMR) With Standard Breast MRI for Breast Cancer Screening

University of Washington1 site in 1 country256 target enrollmentJanuary 3, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Breast Cancer Screening
Sponsor
University of Washington
Enrollment
256
Locations
1
Primary Endpoint
Abnormal interpretation rate
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

This is a single institution, prospective screening trial of women at high risk for developing breast cancer, enriched with women with suspicious lesions on breast MRI which have been recommended for biopsy.

Primary Aim: Measure and compare the diagnostic performance of CESM, ABMR, and standard breast MRI, using the following performance measures: cancer detection rate (CDR), biopsy rate, and cancer yield of biopsy (also known as positive predictive value 3 or PPV3).

Secondary Aims:

  1. Compare screening performance outcome measures of sensitivity, specificity, and area under the receiver operating characteristic curve (AUC) for CESM, ABMR, and standard breast MRI. This will determine the feasibility of each modality as an alternative to standard breast MRI and provide valuable pilot data for designing a larger clinical trial to evaluate non-inferiority of either or both modalities.
  2. Breast cancer characteristics (size, histologic subtype, node-positivity, AJCC stage) will be assessed in the overall cohort, and stratified by mode of detection for each modality(screen-detected versus interval).
Registry
clinicaltrials.gov
Start Date
January 3, 2018
End Date
December 31, 2022
Last Updated
3 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Able and willing to provide signed declaration of informed consent or have a legally authorized representative provide signed declaration of informed consent for participation in all study procedures;
  • Women aged ≥18 years at the time of enrollment
  • Referred clinically for breast MRI for any indication

Exclusion Criteria

  • Known allergy or contraindication to iodinated contrast
  • Are currently pregnant based on urine pregnancy test
  • Have breast implants
  • Are lactating

Outcomes

Primary Outcomes

Abnormal interpretation rate

Time Frame: 2 years

Abnormal interpretation rates for each modality (CESM, abbreviated breast MRI, standard breast MRI)

Secondary Outcomes

  • Negative predictive value(3 years)
  • Cancer detection rate(3 years)
  • Biopsy rate(2 years)
  • Sensitivity(2 years)
  • Positive predictive value for biopsy recommendation (PPV2)(3 years)
  • Specificity(2 years)

Study Sites (1)

Loading locations...

Similar Trials